Company: IMRX
Filing Date: 2025-08-13
Form Type: 10-Q
Source: 0001790340-25-000104
Chunk: 353

Company: Immuneering Corp
Filing Date: 2025-08-13
Form: 10-Q
Item: Part I, Item 1
Chunk 353
---
1,245 98 7.9 %Facilities and other expenses658 649 9 1.4 %Depreciation/amortization122 123 (1)(0.8)%Total research and development$21,925 $21,854 $71 0.3 %

Research and development expenses increased by approximately $0.1 million, or 0.3%, to approximately $21.9 million for the six months ended June 30, 2025 as compared to approximately $21.9 million for the six months ended June 30, 2024. The increase of approximately $0.1 million was primarily due to an increase of approximately $0.6 million related to direct research and development expenses, of which there was an approximately $2.0 million increase in expenses related to atebimetinib (IMM-1-104), offset by a $0.3 million decrease in expenses related to IMM-6-415 driven by decreased manufacturing and preclinical spend, and by a $1.1 million decrease in spend for earlier stage programs. The remaining variance was attributable to decreased indirect research and development costs of approximately $528 thousand, driven by a $0.6 million decrease associated with employee-related costs, offset by minor increases in stock-based compensation expense, facilities and other expenses, in the aggregate. 

30

General and Administrative

The following table summarizes the components of general and administrative expenses for the periods indicated:

Six Months Ended June 30,Change20252024$%(in thousands, except percentages)Employee-related costs$4,271 $4,243 $28 0.7 %Stock-based compensation expense1,874 1,891 (17)(0.9)%Professional fees1,569 1,356 213 15.7 %Facilities and other allocated expenses126 156 (30)(19.2)%Other461 724 (263)(36.3)%Total general and administrative$8,301 $8,370 $(69)(0.8)%

General and administrative expenses decreased by approximately $69 thousand, or 0.8%, to approximately $8.3 million for the six months ended June 30, 2025 compared to approximately $8.4 million for the six months ended June 30, 2024. The decrease of approximately $69 thousand was primarily due to decreased stock-based compensation expense of approximately $17 thousand, a decrease of